Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure.
This study investigates the pharmacokinetics of a low molecular weight heparin (Fraxiparine) after a single bolus intravenous injection of 100 antifactor Xa IC U.kg-1 in 3 groups of patients affected by chronic renal insufficiency of various severity: group A (n = 7) was composed of hemodialyzed patients; groups; B (n = 7) had a creatinine clearance ranging from 10 to 20 ml.min-1 and group C (n = 5) from 30 to 50 ml.min-1. There was no significant difference between the pharmacokinetic parameters determined in the 3 groups of patients and no correlation between these parameters and the creatinine clearance. However, when compared to the values established in a group of 12 healthy volunteers, the half-life of disappearance of the antifactor Xa activity was significantly prolonged. Therefore it is advised to monitor antifactor Xa activity in patients affected by chronic renal insufficiency of any severity to avoid a possible accumulation phenomenon.
Goudable
C
C
Service de Néphrologie, Hôpital de Rangueil, France.
Saivin
S
S
Houin
G
G
Sie
P
P
Boneu
B
B
Tonthat
H
H
Suc
J M
JM
D000328:Adult; D000368:Aged; D065427:Factor Xa Inhibitors; D006207:Half-Life; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism*; D008875:Middle Aged
D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight